ABOUT THE PRODUCT
Dersimelagon (MT-7117) is a novel oral treatment being developed for Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP). Clinical trial data has shown promising results, and we are committed to advancing this potential therapy.
Information is owner-confirmed
Last updated 1 month ago
Price range
Other products/services from Tanabe Pharma America
RADICAVA (edaravone)
Pharmaceutical
N/A
Tanabe Pharma America
United States (US)